MTNB Matinas BioPharma Holdings Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: MTNB

Price (delayed)

$0.2001

Market cap

$43.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.11

Enterprise value

$40.78M

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care for patients in areas of significant unmet medical need. Company leadership has ...

Highlights
Matinas BioPharma Holdings's debt has decreased by 12% YoY and by 3.8% QoQ
The EPS has grown by 8% YoY
The gross profit has surged by 98% year-on-year but it has declined by 20% since the previous quarter
Matinas BioPharma Holdings's revenue has soared by 98% YoY but it has decreased by 20% from the previous quarter
The company's equity fell by 40% YoY and by 17% QoQ
The company's quick ratio fell by 35% QoQ and by 16% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.matinasbiopharma.com
Peers: OMGA

Key stats

What are the main financial stats of MTNB
Market
Shares outstanding
217.26M
Market cap
$43.47M
Enterprise value
$40.78M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.88
Price to sales (P/S)
10.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.52
Earnings
Revenue
$4.28M
EBIT
-$21.26M
EBITDA
-$20.34M
Free cash flow
-$15.26M
Per share
EPS
-$0.11
Free cash flow per share
-$0.07
Book value per share
$0.11
Revenue per share
$0.02
TBVPS
$0.13
Balance sheet
Total assets
$29.79M
Total liabilities
$6.64M
Debt
$3.71M
Equity
$23.15M
Working capital
$16.76M
Liquidity
Debt to equity
0.16
Current ratio
6.19
Quick ratio
5.66
Net debt/EBITDA
0.13
Margins
EBITDA margin
-474.7%
Gross margin
100%
Net margin
-496.3%
Operating margin
-545.3%
Efficiency
Return on assets
-57.9%
Return on equity
-70.7%
Return on invested capital
-73%
Return on capital employed
-80%
Return on sales
-496.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MTNB stock price

How has the Matinas BioPharma Holdings stock price performed over time
Intraday
-2.53%
1 week
-7.53%
1 month
-6.93%
1 year
-69.31%
YTD
-59.98%
QTD
53.92%

Financial performance

How have Matinas BioPharma Holdings's revenue and profit performed over time
Revenue
$4.28M
Gross profit
$4.28M
Operating income
-$23.36M
Net income
-$21.26M
Gross margin
100%
Net margin
-496.3%
The gross profit has surged by 98% year-on-year but it has declined by 20% since the previous quarter
Matinas BioPharma Holdings's revenue has soared by 98% YoY but it has decreased by 20% from the previous quarter
Matinas BioPharma Holdings's net margin has surged by 55% YoY but it has decreased by 28% QoQ
MTNB's operating margin has surged by 54% year-on-year but it is down by 29% since the previous quarter

Growth

What is Matinas BioPharma Holdings's growth rate over time

Valuation

What is Matinas BioPharma Holdings stock price valuation
P/E
N/A
P/B
1.88
P/S
10.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.52
The EPS has grown by 8% YoY
The stock's price to book (P/B) is 45% less than its 5-year quarterly average of 3.5 and 23% less than its last 4 quarters average of 2.5
The company's equity fell by 40% YoY and by 17% QoQ
Matinas BioPharma Holdings's revenue has soared by 98% YoY but it has decreased by 20% from the previous quarter
MTNB's P/S is 42% below its last 4 quarters average of 17.8

Efficiency

How efficient is Matinas BioPharma Holdings business performance
The ROS has soared by 55% YoY but it has contracted by 28% from the previous quarter
The ROE is down by 33% year-on-year and by 16% since the previous quarter
The return on assets has declined by 31% year-on-year and by 15% since the previous quarter
Matinas BioPharma Holdings's ROIC has decreased by 13% from the previous quarter and by 13% YoY

Dividends

What is MTNB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MTNB.

Financial health

How did Matinas BioPharma Holdings financials performed over time
Matinas BioPharma Holdings's total assets has decreased by 37% YoY and by 12% QoQ
The company's quick ratio fell by 35% QoQ and by 16% YoY
Matinas BioPharma Holdings's debt is 84% lower than its equity
The company's debt to equity rose by 45% YoY and by 14% QoQ
The company's equity fell by 40% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.